Brokerages Set Eagle Pharmaceuticals Inc. (EGRX) PT at $90.24
Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the firm. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $90.24.
A number of research firms have recently commented on EGRX. Piper Jaffray Cos. restated a “buy” rating and issued a $91.00 price objective on shares of Eagle Pharmaceuticals in a research report on Saturday, October 15th. Mizuho raised their price objective on shares of Eagle Pharmaceuticals from $47.00 to $65.00 and gave the company a “neutral” rating in a research report on Tuesday, August 16th. William Blair raised their price objective on shares of Eagle Pharmaceuticals from $83.00 to $97.00 and gave the company an “outperform” rating in a research report on Wednesday, November 2nd. RBC Capital Markets restated an “outperform” rating and issued a $93.00 price objective (up from $80.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 3rd. Finally, Royal Bank Of Canada raised their price objective on shares of Eagle Pharmaceuticals from $80.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd.
Eagle Pharmaceuticals (NASDAQ:EGRX) opened at 79.50 on Wednesday. Eagle Pharmaceuticals has a 12 month low of $33.02 and a 12 month high of $102.48. The firm has a 50-day moving average of $67.54 and a 200 day moving average of $53.70. The firm has a market capitalization of $1.23 billion, a PE ratio of 51.79 and a beta of 1.37.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.12. The firm earned $37.80 million during the quarter, compared to analyst estimates of $41.04 million. Eagle Pharmaceuticals had a net margin of 20.06% and a return on equity of 25.63%. The company’s quarterly revenue was up 563.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) earnings per share. Equities research analysts forecast that Eagle Pharmaceuticals will post $3.13 earnings per share for the current year.
In other Eagle Pharmaceuticals news, major shareholder Proquest Investments Iv, L.P. sold 99,795 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $61.36, for a total transaction of $6,123,421.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 18.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of EGRX. Janus Capital Management LLC increased its position in Eagle Pharmaceuticals by 2.9% in the second quarter. Janus Capital Management LLC now owns 1,490,229 shares of the specialty pharmaceutical company’s stock valued at $57,805,000 after buying an additional 42,690 shares during the period. BlackRock Fund Advisors increased its position in Eagle Pharmaceuticals by 87.0% in the third quarter. BlackRock Fund Advisors now owns 769,869 shares of the specialty pharmaceutical company’s stock valued at $53,891,000 after buying an additional 358,134 shares during the period. Victory Capital Management Inc. acquired a new position in Eagle Pharmaceuticals during the third quarter valued at approximately $48,318,000. State Street Corp increased its position in Eagle Pharmaceuticals by 64.3% in the first quarter. State Street Corp now owns 629,493 shares of the specialty pharmaceutical company’s stock valued at $25,489,000 after buying an additional 246,262 shares during the period. Finally, First Eagle Investment Management LLC acquired a new position in Eagle Pharmaceuticals during the third quarter valued at approximately $39,774,000.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).
Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.